{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:03:37Z","timestamp":1761962617858,"version":"build-2065373602"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012921","name":"Royal College of Surgeons in Ireland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Focal therapy has been approved by both NICE and EAU for localised prostate cancer treatment as part of a prospective registry; however, it is not yet available in Ireland. This study aims to assess the proportion of patients with prostate cancer who are suitable for this treatment and to assess attitudes amongst specialists in Ireland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with a new prostate cancer diagnosis in a tertiary-referral unit within a 12-month period had their radiological and clinicopathological parameters examined by an expert in the delivery of focal therapy to assess their suitability for treatment. Secondly, a questionnaire addressing current knowledge and attitudes was sent to all consultant urologists and trainees nationally.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Two hundred seven patients were seen in a prostate cancer diagnosis clinic in 2023. Following exclusions, of the 191 patients with clinically localised disease, 50% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200996: 8% GG1; 71% GG2, 16% GG3, 3% GG4) are technically suitable and 27% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200952: 6% GG1; 69% GG2, 19% GG3, 6% GG4) are ideal candidates for focal therapy. 23\/28 trainees and 25\/72 consultants responded to the survey (48%). Ninety-four percent routinely deal with prostate cancer diagnoses; however, almost 90% do not inform patients focal therapy is a treatment option. Forty-four percent of trainees and half of consultant prostatectomists are interested in learning focal treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there is a lack of exposure amongst Irish urologists, there is considerable interest in introducing focal therapy nationally. Up to half of patients with new prostate cancer diagnoses may be suitable for treatment highlighting the potential for developing this service in Ireland.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11845-025-04023-1","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T07:17:39Z","timestamp":1753514259000},"page":"1547-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Focal therapy for prostate cancer in Ireland: addressing the national objective and subjective needs"],"prefix":"10.1007","volume":"194","author":[{"given":"Robert A.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Keane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jody","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Z.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rustom P.","family":"Manecksha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise C.","family":"McLoughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter E.","family":"Lonergan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed S.","family":"Inder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"issue":"2","key":"4023_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41391-020-00315-y","volume":"24","author":"TT Shah","year":"2021","unstructured":"Shah TT, Reddy D, Peters M et al (2021) Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis 24(2):567\u2013574","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"4023_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","volume":"74","author":"S Guillaumier","year":"2018","unstructured":"Guillaumier S, Peters M, Arya M and others (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 74(4):422\u2013429","journal-title":"Eur Urol"},{"issue":"1","key":"4023_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","volume":"16","author":"VJ Gnanapragasam","year":"2018","unstructured":"Gnanapragasam VJ, Bratt O, Muir K and others (2018) The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med 16(1):31","journal-title":"BMC Med"},{"issue":"3","key":"4023_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/pcan.2017.8","volume":"20","author":"KJ Tay","year":"2017","unstructured":"Tay KJ, Scheltema MJ, Ahmed HU and others (2017) Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. Prostate Cancer Prostatic Dis 20(3):294\u2013299","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"4023_CR5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","volume":"84","author":"S Deivasigamani","year":"2023","unstructured":"Deivasigamani S, Kotamarti S, Rastinehad AR and others (2023) Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement. Eur Urol 84(6):547\u2013560","journal-title":"Eur Urol"},{"unstructured":"European Association of Urology. EAU guidelines: prostate cancer - treatment. Arnhem, The Netherlands2023 [cited 2024 May 28th]. Available from: https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment.","key":"4023_CR6"},{"issue":"5","key":"4023_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.euf.2020.09.015","volume":"7","author":"J von Hardenberg","year":"2021","unstructured":"von Hardenberg J, Borkowetz A, Siegel F and others (2021) Potential candidates for focal therapy in prostate cancer in the era of magnetic resonance imaging-targeted biopsy: a large multicenter cohort study. Eur Urol Focus 7(5):1002\u20131010","journal-title":"Eur Urol Focus"},{"unstructured":"Cara Dooley AM, Frank Sullivan, Ray McDermott, Conan Donnelly, Linda Sharp, David Galvin. Irish prostate cancer outcomes research annual report 2018. 2018.","key":"4023_CR8"},{"issue":"6","key":"4023_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bju.15004","volume":"125","author":"CE Lovegrove","year":"2020","unstructured":"Lovegrove CE, Peters M, Guillaumier S and others (2020) Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU evaluation and assessment of treatment (HEAT) registry. BJU Int 125(6):853\u2013860","journal-title":"BJU Int"},{"issue":"3","key":"4023_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.euo.2020.12.008","volume":"4","author":"AS Bates","year":"2021","unstructured":"Bates AS, Ayers J, Kostakopoulos N and others (2021) A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and recommendations for clinical practice and further research. Eur Urol Oncol 4(3):405\u2013423","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"4023_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bju.15883","volume":"131","author":"S Ong","year":"2023","unstructured":"Ong S, Chen K, Grummet J and others (2023) Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int 131(1):20\u201331","journal-title":"BJU Int"},{"issue":"1","key":"4023_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/13696998.2023.2251849","volume":"26","author":"D Reddy","year":"2023","unstructured":"Reddy D, van Son M, Peters M and others (2023) Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis. J Med Econ 26(1):1099\u20131107","journal-title":"J Med Econ"},{"doi-asserted-by":"crossref","unstructured":"Marra G, Ploussard G, Ost P, De Visschere PJL, Briganti A, Gandaglia G, et al. (2018) Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. Urol Oncol 36(12):529.e11-.e22","key":"4023_CR13","DOI":"10.1016\/j.urolonc.2018.08.013"},{"issue":"4","key":"4023_CR14","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1089\/end.2020.0774","volume":"35","author":"M Wenzel","year":"2021","unstructured":"Wenzel M, Borgmann H, Von Hardenberg J and others (2021) Acceptance, Indications and chances of focal therapy in localized prostate cancer: a real-world perspective of urologists in Germany. J Endourol 35(4):444\u2013450","journal-title":"J Endourol"},{"doi-asserted-by":"crossref","unstructured":"Jain AL, Sidana A, Maruf M, Sugano D, Calio B, Wood BJ, et al. (2019) Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer. Urol Oncol 37(3):182.e1-.e8","key":"4023_CR15","DOI":"10.1016\/j.urolonc.2018.11.018"},{"doi-asserted-by":"crossref","unstructured":"Koehler J, Lazarovich A, Tayebi S, Viswanath V, George A, Hsu W-W, et al. (2024) Shifting tides: a survey analysis of urologists' evolving attitudes and practice patterns in focal therapy for prostate cancer","key":"4023_CR16","DOI":"10.21203\/rs.3.rs-4308182\/v1"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04023-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-04023-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-04023-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:01:08Z","timestamp":1761962468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-04023-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4023"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-04023-1","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}